Table 2. Results of univariable and multivariable analyses of overall survival.
| Variables | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Sarcopenia | 1.47 (1.03–2.10) | 0.033 | 1.51 (1.04–2.18) | 0.028 |
| Age ≥ 70 | 1.52 (1.06–2.17) | 0.057 | ||
| Male sex | 1.11 (0.73–1.67) | 0.632 | ||
| ECOG PS ≥ 2 | 2.18 (1.42–3.37) | <0.001 | ||
| HER2(-) | 1.25 (0.86–1.82) | 0.238 | ||
| No response to chemotherapy | 2.23 (1.55–3.22) | <0.001 | 2.47 (1.69–3.61) | <0.001 |
| No 2nd-line therapy | 1.75 (1.22–2.51) | 0.002 | 2.43 (1.64–3.59) | <0.001 |
| Underweight (BMI < 18.5) | 1.40 (0.93–2.12) | 0.105 | ||
| Metastatic sites ≥ 3 | 1.74 (1.14–2.64) | 0.010 | 2.31 (1.49–3.60) | <0.001 |
| Albumin < 3.5 g/dL | 1.56 (1.09–2.23) | 0.016 | 1.50 (1.03–2.19) | 0.033 |
BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HER2, human epidermal growth factor 2; HR, hazard ratio